Dr. Reddy's Laboratories Limited or Xencor, Inc.: Who Manages SG&A Costs Better?

Comparing SG&A strategies of Dr. Reddy's and Xencor.

__timestampDr. Reddy's Laboratories LimitedXencor, Inc.
Wednesday, January 1, 2014387830000007461000
Thursday, January 1, 20154258500000011960000
Friday, January 1, 20164570200000013108000
Sunday, January 1, 20174637200000017501000
Monday, January 1, 20184691000000022472000
Tuesday, January 1, 20194889000000024286000
Wednesday, January 1, 20205012900000029689000
Friday, January 1, 20215455900000038837000
Saturday, January 1, 20226208100000047489000
Sunday, January 1, 202310593100000053379000
Monday, January 1, 202477201000000
Loading chart...

Unlocking the unknown

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Dr. Reddy's Laboratories Limited and Xencor, Inc. offer a fascinating study in contrasts. Over the past decade, Dr. Reddy's has seen its SG&A expenses grow by approximately 173%, peaking in 2023. In contrast, Xencor's expenses have increased by about 615% over the same period, albeit from a much smaller base. This disparity highlights the different scales and strategies of these companies. While Dr. Reddy's operates on a global scale, Xencor, a smaller biotech firm, is in a growth phase, investing heavily in research and development. The data for 2024 is incomplete, but the trend suggests that both companies are navigating their financial strategies in unique ways, reflecting their distinct market positions and growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025